FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387379110> ?p ?o ?g. }

• W4387379110 abstract "Abstract Disclosure: A. Skoczylas: None. A. Kluza: None. E.C. Lubocka: None. W. Mularczyk: None. M. Zyla: None. K. Fortuna: None. I. Linkert: None. J. Raniszewska: None. M. Skoczylas: None. P. Piwkowski: None. A. Golebiowska: None. A. Partyka: None. P. Wozniak: None. D. Jedrzejuk: None. The aim of this study was to estimate the levels of thryoid antibodies: aTPO, aTG and TRAb in basic conditions and after subsequent radioactive iodine (I-131) administrations in patients with huge nodular goiter and to assess whether subsequent doses of I-131 alter these levels. Methods 260 patients 199F/61M aged 41-88 years with mean TSH concentration of 1.0 and nodular goiter of mean weight 93g (35-364g) assessed on iodine scintigraphy, with contraindications to surgical treatment were enrolled to this study. These patients were qualified for I-131 cytoreduction. The activity planned for treatment was divided into fractionated doses of 0.8 GBq, which were given at 3-month intervals up to 4 times. Before each treatment, as well as 3 months after the last one, immunological and biochemical tests were performed. Elevated levels of aTPO and aTG were confirmed in 33 qualified patients. Statistics The statistical significance of differences in antibody concentrations between rounds was measured using the Skillings-Mack nonparametric test (SM-t). Dunn-Bonferroni post hoc method (DB) was used to assess the significance of pairwise differences in antibody levels between studies. Correlations between changes in antibody levels and goiter parameters were studied using the Spearman's Rank correlation - a value of p&lt;0.05 was taken as significant. Results The SM-t showed that there was a statistical difference in TRAb resulting from the I-131 administration SM-t=42.35, p&lt;0.001. DB test showed a significant increase in TRAb levels compared to baseline Me=0.30 from the second I-131 administration Me=0.35, p&lt;0.01, but exceeded the upper normal range in only 6 patients. The first treatment did not change TRAb levels Me=0.30, p&gt;0.05 significantly. The SM-t showed a statistical difference in aTG levels SM-t=38.74, p&lt;0.01. DB analysis showed that compared to the baseline Me=11.60, the level had already changed significantly from the first administration of I-131 Me=13.50, p&lt;0.01, and retreatments no longer changed the concentration of aTG significantly. Retreatments resulted in significant differences in aTPO SM-t=16.08, p&lt;0.01, but DB test did not specifically indicates between which I-131 administrations these differences were significant. In the group with baseline immune abnormalities, statistical analysis indicated the existence of differences in TRAb SM-t=1.63, p&lt;0.05 and aTPO SM-t=17.72, p&lt;0.05 levels, but no significant correlation was observed between changes in the level of tested antibodies and changes in descriptive goiter parameters. Conclusion Initial I-131 therapy did not change the TRAb concentration, but subsequent treatments led to a significant increase in TRAb concentrations compared to baseline measurements. The concentration of aTG significantly increased immediately after the first I-131 therapy but subsequent treatments no longer changed their concentration Presentation: Friday, June 16, 2023" @default.
• W4387379110 created "2023-10-06" @default.
• W4387379110 creator A5013337799 @default.
• W4387379110 creator A5021949137 @default.
• W4387379110 creator A5028390225 @default.
• W4387379110 creator A5055864778 @default.
• W4387379110 creator A5056466339 @default.
• W4387379110 creator A5068706567 @default.
• W4387379110 creator A5073670073 @default.
• W4387379110 creator A5082905378 @default.
• W4387379110 creator A5093006403 @default.
• W4387379110 creator A5093006404 @default.
• W4387379110 creator A5093006405 @default.
• W4387379110 creator A5093006406 @default.
• W4387379110 creator A5093006407 @default.
• W4387379110 creator A5093006408 @default.
• W4387379110 date "2023-10-01" @default.
• W4387379110 modified "2023-10-16" @default.
• W4387379110 title "FRI534 Influence Of Radioiodine Therapy Of Huge Thyroid Goiter On The Development Of Autoimmune Thyroid Disease In Retreated Patents" @default.
• W4387379110 doi "https://doi.org/10.1210/jendso/bvad114.1879" @default.
• W4387379110 hasPublicationYear "2023" @default.
• W4387379110 type Work @default.
• W4387379110 citedByCount "0" @default.
• W4387379110 crossrefType "journal-article" @default.
• W4387379110 hasAuthorship W4387379110A5013337799 @default.
• W4387379110 hasAuthorship W4387379110A5021949137 @default.
• W4387379110 hasAuthorship W4387379110A5028390225 @default.
• W4387379110 hasAuthorship W4387379110A5055864778 @default.
• W4387379110 hasAuthorship W4387379110A5056466339 @default.
• W4387379110 hasAuthorship W4387379110A5068706567 @default.
• W4387379110 hasAuthorship W4387379110A5073670073 @default.
• W4387379110 hasAuthorship W4387379110A5082905378 @default.
• W4387379110 hasAuthorship W4387379110A5093006403 @default.
• W4387379110 hasAuthorship W4387379110A5093006404 @default.
• W4387379110 hasAuthorship W4387379110A5093006405 @default.
• W4387379110 hasAuthorship W4387379110A5093006406 @default.
• W4387379110 hasAuthorship W4387379110A5093006407 @default.
• W4387379110 hasAuthorship W4387379110A5093006408 @default.
• W4387379110 hasBestOaLocation W43873791101 @default.
• W4387379110 hasConcept C126322002 @default.
• W4387379110 hasConcept C134018914 @default.
• W4387379110 hasConcept C2776254400 @default.
• W4387379110 hasConcept C2776652619 @default.
• W4387379110 hasConcept C2778707442 @default.
• W4387379110 hasConcept C2779761222 @default.
• W4387379110 hasConcept C2989005 @default.
• W4387379110 hasConcept C3018694869 @default.
• W4387379110 hasConcept C526584372 @default.
• W4387379110 hasConcept C65409693 @default.
• W4387379110 hasConcept C71924100 @default.
• W4387379110 hasConcept C90924648 @default.
• W4387379110 hasConceptScore W4387379110C126322002 @default.
• W4387379110 hasConceptScore W4387379110C134018914 @default.
• W4387379110 hasConceptScore W4387379110C2776254400 @default.
• W4387379110 hasConceptScore W4387379110C2776652619 @default.
• W4387379110 hasConceptScore W4387379110C2778707442 @default.
• W4387379110 hasConceptScore W4387379110C2779761222 @default.
• W4387379110 hasConceptScore W4387379110C2989005 @default.
• W4387379110 hasConceptScore W4387379110C3018694869 @default.
• W4387379110 hasConceptScore W4387379110C526584372 @default.
• W4387379110 hasConceptScore W4387379110C65409693 @default.
• W4387379110 hasConceptScore W4387379110C71924100 @default.
• W4387379110 hasConceptScore W4387379110C90924648 @default.
• W4387379110 hasIssue "Supplement_1" @default.
• W4387379110 hasLocation W43873791101 @default.
• W4387379110 hasOpenAccess W4387379110 @default.
• W4387379110 hasPrimaryLocation W43873791101 @default.
• W4387379110 hasRelatedWork W2036521104 @default.
• W4387379110 hasRelatedWork W2057252846 @default.
• W4387379110 hasRelatedWork W2351921826 @default.
• W4387379110 hasRelatedWork W2358633025 @default.
• W4387379110 hasRelatedWork W2359871188 @default.
• W4387379110 hasRelatedWork W2392107066 @default.
• W4387379110 hasRelatedWork W2392543696 @default.
• W4387379110 hasRelatedWork W3029171990 @default.
• W4387379110 hasRelatedWork W3201851107 @default.
• W4387379110 hasRelatedWork W3208354384 @default.
• W4387379110 hasVolume "7" @default.
• W4387379110 isParatext "false" @default.
• W4387379110 isRetracted "false" @default.
• W4387379110 workType "article" @default.